• 1
    Horner MJ, Ries LAG, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2006. Based on November 2008 SEER data submission, posted to the SEER web site, 2009. Bethesda, MD: National Cancer Institute. Available at: Accessed on November 15, 2009.
  • 2
    Peto R, Boreham J, Clarke M, et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000; 355: 1822.
  • 3
    Dignam JJ. Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin. 2000; 50: 50-64.
  • 4
    Jones LA, Brawley O, Johnson-Thompson M, et al. Overview of the summit meeting evaluating research in African-American women. Cancer. 2003; 97: 207-210.
  • 5
    Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst. 2002; 94: 471-473.
  • 6
    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race, sex-, and age-based disparities. JAMA. 2004; 291: 2720-2726.
  • 7
    Healthy People 2010: Understanding and improving health. Washington, DC: Department of Health and Human Services, Office of Disease Prevention and Health Promotion; 2000. Available at: Accessed July 4, 2009.
  • 8
    Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-2502.
  • 9
    Newman LA. Breast cancer in African-American women. Oncologist. 2005; 10: 1-14.
  • 10
    Newman LA, Martin IK. Disparities in breast cancer. Curr Probl Cancer. 2007; 31: 134-156.
  • 11
    Newman LA, Bunner S, Carolin K, et al. Ethnicity related differences in the survival of young breast carcinoma patients. Cancer. 2002; 95: 21-27.
  • 12
    Stark AT, Claud S, Kapke A, et al. Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu. Cancer. 2005; 104: 2189-2196.
  • 13
    Stark A, Kapke A, Schultz D, et al. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in white women: findings from a prospective cohort study of African-American and white-American women. Breast Cancer Res Treat. 2008; 107: 405-414.
  • 14
    Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer. 2005; 103: 164-173.
  • 15
    Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11: 155-168.
  • 16
    Wang S, Saboorian MH, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol. 2000; 53: 374-381.
  • 17
    Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
  • 18
    Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
  • 19
    Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006; 19: 264-271.
  • 20
    Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer. 2007; 110: 876-884.
  • 21
    Lund MJ, Butler EN, Bumpers HL, et al. High prevalence of triple-negative tumors in an urban cancer center. Cancer. 2008; 113: 608-615.
  • 22
    Moran MS, Yang Q, Harris LN, et al. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer. 2008; 113: 2565-2574.
  • 23
    Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009; 113: 357-370.
  • 24
    Anderson WF, Althuis MD, Brinton LA, et al. Is male breast cancer similar or different than female breast cancer?. Breast Cancer Res Treat. 2004; 83: 77-86.
  • 25
    O'Malley C, Shema S, White E, et al. Incidence of male breast cancer in California, 1988-2000: racial/ethnic variation in 1759 men. Breast Cancer Res Treat. 2005; 93: 145-150.
  • 26
    Struewing JP, Abeliovich D, Peretz T, et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995; 11: 198-200.
  • 27
    Oddoux C, Struewing JP, Clayton CM, et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996; 14: 188-190.
  • 28
    Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst. 1999; 91: 1241-1247.
  • 29
    Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol. 2009; 27: 4515-4521.
  • 30
    Bird PA, Hill AG, Houssami N. Poor hormone receptor expression in East African breast cancer: evidence of a biologically different disease?. Ann Surg Oncol. 2008; 15: 1983-1988.
  • 31
    Gordon NH. Socioeconomic factors and breast cancer in black and white Americans. Cancer Metastasis Rev. 2003; 22: 55-65.
  • 32
    Carnon AG, Ssemwogerere A, Lamont DW, et al. Relation between socioeconomic deprivation and pathological prognostic factors in women with breast cancer. BMJ. 1994; 309: 1054-1057.
  • 33
    Halmin M, Bellocco R, Lagerlund M, et al. Long-term inequalities in breast cancer survival—a ten year follow-up study of patients managed within a National Health Care System (Sweden). Acta Oncol. 2008; 47: 216-224.
  • 34
    Bowen RL, Duffy SW, Ryan DA, et al. Early onset of breast cancer in a group of British black women. Br J Cancer. 2008; 98: 277-281.
  • 35
    Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results program at the National Cancer Institute. J Natl Cancer Inst. 2005; 97: 966-975.
  • 36
    Anderson WF, Chatterjee N, Ershler WB, et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002; 76: 27-36.